Mithra Announces Details of EUR 23.5 Million Private Placement

Liege, Belgium, 21 June 2022 –07.30 CET – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the “Company” or “Mithra”), a company dedicated to women’s health, today announces that it received subscription commitments from professional, qualified, institutional and other private investors for an aggregate amount of EUR 23.5 million, to subscribe for an aggregate of 3,871,471 new ordinary shares of the Company (being approximately 8.4% of the Company’s outstanding shares) at an issue price of EUR 6.07 per share, representing a 5% discount to the closing share price on Friday 17 June 2022 (the “Private Placement”).

Mithra Announces Intention to Proceed with Private Placement

Liege, Belgium, 20 June 2022 – 07:45 CEST – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the “Company” or “Mithra”), a company dedicated to women’s health, today announces its intention to proceed with an equity raise for an aggregate minimum amount of EUR 20 million via a private placement of new ordinary shares with certain professional, qualified, institutional and other private investors only (the “Private Placement”).

Mithra Announces the Resignation of François Fornieri As Non-Executive Director

Liege, Belgium, 20 June 2022 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that Mr. François Fornieri resigned from his non-executive director mandate of the Company. Mr. Fornieri ’s decision, founder and major shareholder of the Company, is based on personal reasons.

Publication of Transparency Notifications Received from Goldman Sachs

Liege, Belgium, 13 June 2022 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received two notifications of transparency from Goldman Sachs Group, Inc., with registered offices at Corporation Trust Center, 1209 Orange Street, Wilmington, DE 19801, USA, on 8 & 9, June 2022.

Exercise of a Call Option from Goldman Sachs and Additional Information on the Financing Strategy

Liege, Belgium, 2 June 2022 – 7:30 CET – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the “Company” or “Mithra”), a company dedicated to Women’s Health, today announces that Goldman Sachs International (“GSI”) has elected to exercise the last call option in relation to the outstanding drawdown of EUR 5 million, and provides additional information on its financing strategy.

Mithra Issues a Put Option Notice Under Capital Agreement with LDA Capital

Liege, Belgium, 13 May 2022 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the issuance of a put option notice, according to the terms of the capital commitment agreement signed with LDA Capital Limited on April 24, 2020. Under the terms of this agreement extended in April 2022, LDA Capital commits an amount of up to EUR 75 million in cash within a maximum of five years (until April 2025) in exchange for new ordinary shares in Mithra. This is the fourth put option notice related to this agreement. The first three drawings resulted in the issuance of 916,153 shares for a total amount of approximately EUR 17 million, leaving EUR 58 million available to Mithra.

Presentation of Donesta® Phase 3 Topline Efficacy Results at the 20th ISGE World Congress

Liege, Belgium, 12 May 2022 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, announces that several presentations focusing on therapeutic opportunities for estetrol (E4) will be held at the 20th World Congress of the International Society of Gynecological Endocrinology (ISGE) taking place from 11-14 May 2022 in Florence, Italy. A selection of these presentations will be made available in the coming days in the investors section of the company’s website.

Publication of a Transparency Notification Received from Glenernie Capital

Liege, Belgium, 06 May 2022 – 17:45 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a notification of transparency from Glenernie Capital Ltd, with registered offices at Smithson Plaza, 13th Floor, 25 St. James’s Street, London SW1A 1HA, on 3, May 2022. Glenernie Capital has notified Mithra that it has exceeded the statutory 3% threshold on 28, April 2022.

Publication of Transparency Notifications Received from Goldman Sachs

Liege, Belgium, 29 April 2022 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received two notifications of transparency from Goldman Sachs Group, Inc., with registered offices at Corporation Trust Center, 1209 Orange Street, Wilmington, DE 19801, USA, on 6, April 2022.

Goldman Sachs has notified Mithra on 27, April 2022 that it has exceeded the statutory 3% threshold on 22, April 2022 and then has crossed downwards the statutory 3% threshold on 25, April 2022.

Mithra CDMO Announces Collaboration with MedinCell for the Development of Injectable Products for Malaria and Transplant Rejection

Liege, Belgium, 26 April 2022 – 7:30 CEST – Mithra (Euronext Brussels: MITRA) today announces a collaboration with MedinCell for the development of two long-acting injectable products in its CDMO based in Liège.

Mithra CDMO offers a complete spectrum of solutions from early drug development, clinical batches and commercial manufacturing of complex polymeric products (vaginal ring, implants) and complex liquid injectables and biologicals in vials, pre-filled syringes or cartridges.